0001213900-26-057841
SEC filingQ2 FY2026 net loss widened significantly to -$26.6M, driven by a large one-time contract cancellation fee, partially offset by initial LYMPHIR revenue of $1.7M and an 80.3% gross margin.
Citius Oncology recorded its first meaningful product revenue of $1.7M in Q2 FY2026, following the commercial launch of LYMPHIR in December 2025. The gross profit of $1.3M translated to an 80.3% gross margin, reflecting the high-value nature of this oncology immunotherapy. Management noted that initial accounts are placing repeat orders, and on April 29, 2026, the company announced its first shipment to Europe through a regional distribution partner, indicating early international expansion. However, as a newly launched product, gross-to-net adjustments rely on estimates from distributor inventory and market data until sufficient history accumulates, introducing some revenue uncertainty.
Management expressed confidence that revenues will increase as LYMPHIR gains market acceptance, citing repeat orders and the European expansion. The company has engaged Jefferies LLC to evaluate strategic alternatives aimed at maximizing shareholder value. However, the path to profitability remains uncertain given the early stage of commercialization, ongoing operating losses, and the need for substantial additional financing to meet milestone payments and purchase commitments. The May 2026 financings provide a temporary cushion, but the company's long-term viability depends on successful market penetration and further capital raises.